Corvus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
CRVS 01.07.2025
Date of Upcoming Event:2025-01-15
Name of Upcoming Event:43rd Annual J.P. Morgan Healthcare Conference

About Gravity Analytica
Recent News
- 01.15.2025 - 43rd Annual J.P. Morgan Healthcare Conference
- 01.13.2025 - Corvus Pharmaceuticals Announces Data from Cohort 2 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
- 01.07.2025 - Corvus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Recent Filings
An audio webcast of the presentation will be available live and for 30 days following the event. The webcast may be accessed via theinvestor relationssection of the Corvus website.
About Corvus PharmaceuticalsCorvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of cancer and immune diseases. The Company’s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visitwww.corvuspharma.com.
INVESTOR CONTACT:
MEDIA CONTACT:

Source: Corvus Pharmaceuticals, Inc.